Biocardia announces fda approval of its ind for nk1r+ mesenchymal stem cells for the treatment of patients recovering from acute respiratory distress due to covid-19

Phase i/ii trial initiation expected in 3q 2022 phase i/ii trial initiation expected in 3q 2022

BCDA Ratings Summary

BCDA Quant Ranking